NCT06783361Completed
Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients
Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients: Comparison Of The Effectiveness Of Bilateral Theta Bursts With Unilateral Theta Bursts
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
Depression is the leading cause of disability worldwide and around 800,000 suicides occur each year. According to the World Health Organization, major depressive disorder (MDD) is expected to be the leading cause of the global burden of disease by 2030. One third of MDD patients do not respond to first-line pharmacologic and psychotherapeutic antidepressant treatments. New antidepressant treatments that are safe, tolerable, fast-acting, durable and effective are needed. Transcranial magnetic stimulation (TMS) is a promising form of non-invasive brain stimulation with rapid antidepressant and suicide prevention effects in MDD. TMS applied to the left dorsolateral prefrontal cortex (DLPFC) is a non-invasive brain stimulation technique approved by the US Food and Drug Administration (FDA) for treatment-resistant depression. TMS involves passing an electric current through a magnetic coil placed on the surface of the scalp, producing a high-intensity magnetic field that travels through the scalp, skull and meninges, stimulating neuronal tissue. This in turn causes changes in functional connectivity. The mechanism of TMS on core depressive symptoms is hypothesized to be mediated in part through indirect inhibitory functional connectivity from the left DLPFC to the subgenual anterior cingulate cortex (sgACC).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 13 Dec 2024
- Start date
- 1 Nov 2024
- Primary completion date
- 1 May 2025
- Lead sponsor
- Ataturk University
- Diseases
- Depression
- NCT number
- NCT06783361
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 1 Nov 2024 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having a foreign body such as a pacemaker, intracranial implant that can magnetically interact
Other illness
- Diagnosed with a neurological or metabolic disease that affects cognitive functions (Systemic diseases such as diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic renal failure, Parkinson's disease, multiple sclerosis, polyneuropathy, inflammatory rheumatologic disease and malignancies)
- Unstable or acute medical conditions
- Having a primary psychiatric disorder other than major depressive disorder
Other
- Hearing and visual impairments that prevent communication
- Pregnancy or breastfeeding
- Being diagnosed with severe MDD with psychotic features
Who the study is looking for
- 18 to 65 years old
- Patients diagnosed with Major Depressive Disorder according to DSM 5 and the severity of their illness
- Scoring 7 points or more on the Maudsley staging method
- Having depression unresponsive to 2 different antidepressants
- No clinical mental retardation
- Agree to participate in the study
- Hamilton Depression Rating Scale-17 \[HDRS\] score of 20 or higher
- Montgomery Asberg Depression Rating Scale \[MADRS\] score of 20 or above
- Being right hand dominant
- Having used the same antidepressant at the same dose for the last 4 weeks
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Atatürk University Coordinator of this site? Confirm its status | Erzurum | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.